News

The Company has retained Stifel, Nicolaus & Company, Incorporated to serve as its financial advisor in the process. Aviragen Therapeutics does not have a defined timeline for the

The study, dubbed OPTIC, assessed the safety and efficacy of once-daily, IV-to-oral omadacycline in comparison to IV-to-oral moxifloxacin in the treatment of CABP in adults. In the clinical trial featuring 774

Imbruvica is an oral and once-daily therapy, which suppresses Bruton's tyrosine kinase (BTK) protein, which is a signaling molecule in the B-cell receptor signaling complex that will spread

Formerly known under the developmental name SD-809, austedo has now become the first deuterated product to get FDA approval and also the second drug approved in HD. Previously

The approval marks the first targeted treatment approved for the patient population, who previously had few treatment options, in all 28 member states of the European Union (EU),

Sucampo funded the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common stock and $170 million of cash on hand; no external financing was utilized.

Ogeda is engaged in the discovery and development of small molecule drugs that target G-protein coupled receptors (GPCRs). Under the deal, Astellas will pay around €500m for 100% equity

The trial will feature 80-120 patients having the severe form of the disease who will be randomized to receive treatment with either mepolizumab or placebo when added to the

The results were presented in an oral session (OR08-1) at ENDO 2017, the Endocrine Society's Annual Meeting in Orlando, Fla. In the study, postmenopausal women with low bone